Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ Read more →

‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing Read more →

Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones Read more →